PL2268310T3 - Zastosowanie przeciwciała anty-cd20 typu ii o zwiększonej cytotoksyczności komórkowej zależnej od przeciwciał (adcc) w połączeniu z cyklofosfamidem, winkrystyną i doksorubicyną do leczenia chłoniaków nieziarniczych - Google Patents
Zastosowanie przeciwciała anty-cd20 typu ii o zwiększonej cytotoksyczności komórkowej zależnej od przeciwciał (adcc) w połączeniu z cyklofosfamidem, winkrystyną i doksorubicyną do leczenia chłoniaków nieziarniczychInfo
- Publication number
- PL2268310T3 PL2268310T3 PL09723808T PL09723808T PL2268310T3 PL 2268310 T3 PL2268310 T3 PL 2268310T3 PL 09723808 T PL09723808 T PL 09723808T PL 09723808 T PL09723808 T PL 09723808T PL 2268310 T3 PL2268310 T3 PL 2268310T3
- Authority
- PL
- Poland
- Prior art keywords
- antibody
- doxorubicine
- adcc
- lymphomas
- vincristine
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/475—Quinolines; Isoquinolines having an indole ring, e.g. yohimbine, reserpine, strychnine, vinblastine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
- A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/664—Amides of phosphorus acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
- A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
- A61K31/704—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2887—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against CD20
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
- C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- Molecular Biology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Oncology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Genetics & Genomics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP08005554 | 2008-03-25 | ||
| EP08007172 | 2008-04-11 | ||
| EP09723808.3A EP2268310B1 (en) | 2008-03-25 | 2009-03-23 | Use of a type ii anti-cd20 antibody with increased antibody dependent cellular cytotoxicity (adcc) in combination with cyclophosphamide, vincristine and doxorubicine for treating non-hodgkin' s lymphomas |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PL2268310T3 true PL2268310T3 (pl) | 2017-08-31 |
Family
ID=40872445
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PL09723808T PL2268310T3 (pl) | 2008-03-25 | 2009-03-23 | Zastosowanie przeciwciała anty-cd20 typu ii o zwiększonej cytotoksyczności komórkowej zależnej od przeciwciał (adcc) w połączeniu z cyklofosfamidem, winkrystyną i doksorubicyną do leczenia chłoniaków nieziarniczych |
Country Status (31)
| Country | Link |
|---|---|
| US (6) | US20090246197A1 (pl) |
| EP (1) | EP2268310B1 (pl) |
| JP (3) | JP5547709B2 (pl) |
| KR (1) | KR101280716B1 (pl) |
| CN (2) | CN107198772A (pl) |
| AR (1) | AR072947A1 (pl) |
| AU (1) | AU2009228616B2 (pl) |
| BR (1) | BRPI0909227B8 (pl) |
| CA (1) | CA2716884C (pl) |
| CL (1) | CL2009000713A1 (pl) |
| CR (1) | CR11687A (pl) |
| CY (1) | CY1117984T1 (pl) |
| DK (1) | DK2268310T3 (pl) |
| ES (1) | ES2592312T3 (pl) |
| HR (1) | HRP20161301T1 (pl) |
| HU (1) | HUE028828T2 (pl) |
| IL (1) | IL208018A (pl) |
| LT (1) | LT2268310T (pl) |
| MA (1) | MA32140B1 (pl) |
| MX (1) | MX2010009647A (pl) |
| MY (1) | MY163544A (pl) |
| NZ (1) | NZ587284A (pl) |
| PE (1) | PE20091821A1 (pl) |
| PL (1) | PL2268310T3 (pl) |
| PT (1) | PT2268310T (pl) |
| RS (1) | RS55258B1 (pl) |
| RU (1) | RU2589704C2 (pl) |
| SI (1) | SI2268310T1 (pl) |
| TW (1) | TWI500624B (pl) |
| WO (1) | WO2009118142A1 (pl) |
| ZA (1) | ZA201006190B (pl) |
Families Citing this family (33)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2961563B2 (ja) | 1991-01-29 | 1999-10-12 | 株式会社トーキン | パルス発生用磁気ワイヤの製造方法 |
| LT2077282T (lt) | 2003-11-05 | 2017-03-10 | Roche Glycart Ag | Antigeną surišančios molekulės su padidintu fc receptoriaus surišimo giminingumu ir efektoriaus funkcija |
| DK2268310T3 (en) * | 2008-03-25 | 2016-08-15 | Roche Glycart Ag | APPLICATION OF A TYPE II ANTI-CD20 ANTIBODY WITH ENHANCED ANTIBODY-DEPENDENT CELLULAR CYTOTOXICITY (ADCC) IN COMBINATION WITH CYCLOPHOSPHAMIDE, VINCRISTIN AND DOXORUBICINE TO TREAT NON-HODGINE |
| TW201014605A (en) | 2008-09-16 | 2010-04-16 | Genentech Inc | Methods for treating progressive multiple sclerosis |
| AR078161A1 (es) | 2009-09-11 | 2011-10-19 | Hoffmann La Roche | Formulaciones farmaceuticas muy concentradas de un anticuerpo anti cd20. uso de la formulacion. metodo de tratamiento. |
| MX342405B (es) | 2010-06-03 | 2016-09-28 | Pharmacyclics Inc | El uso de inhibidores de la tirosina quinasa de bruton (btk). |
| RU2013131444A (ru) * | 2010-12-16 | 2015-01-27 | Рош Гликарт Аг | Сочетанная терапия афукозилированным антителом к cd20 и ингибитором mdm2 |
| MX391121B (es) * | 2011-10-19 | 2025-03-19 | Pharmacyclics Llc | Uso de inhibidores de la tirosina cinasa de bruton (btk). |
| US20130302274A1 (en) * | 2011-11-25 | 2013-11-14 | Roche Glycart Ag | Combination therapy |
| EP2877598A1 (en) | 2012-07-24 | 2015-06-03 | Pharmacyclics, Inc. | Mutations associated with resistance to inhibitors of bruton's tyrosine kinase (btk) |
| SG11201604875PA (en) * | 2013-12-17 | 2016-07-28 | Genentech Inc | Methods of treating cancer using pd-1 axis binding antagonists and an anti-cd20 antibody |
| US9603927B2 (en) * | 2014-02-28 | 2017-03-28 | Janssen Biotech, Inc. | Combination therapies with anti-CD38 antibodies |
| US9732154B2 (en) | 2014-02-28 | 2017-08-15 | Janssen Biotech, Inc. | Anti-CD38 antibodies for treatment of acute lymphoblastic leukemia |
| EP3191187B1 (en) | 2014-09-09 | 2021-07-28 | Janssen Biotech, Inc. | Combination therapies with anti-cd38 antibodies |
| TWI721959B (zh) | 2014-12-04 | 2021-03-21 | 美商健生生物科技公司 | 治療急性骨髓性白血病之抗ｃｄ３８抗體 |
| IL254817B2 (en) | 2015-04-08 | 2023-12-01 | Novartis Ag | Cd20 therapies, cd22 therapies, and combination therapies with a cd19 chimeric antigen receptor (car) - expressing cell |
| MX389805B (es) | 2015-05-20 | 2025-03-11 | Janssen Biotech Inc | Anticuerpos anti-cd38 para el tratamiento de amiloidosis de cadena ligera y otras enfermedades malignas hematológicas positivas para cd38. |
| MA46315A (fr) | 2015-06-22 | 2019-08-07 | Janssen Biotech Inc | Polythérapies pour malignités hématologiques avec des anticorps anti-cd38 et des inhibiteurs de la survivine |
| US20170044265A1 (en) | 2015-06-24 | 2017-02-16 | Janssen Biotech, Inc. | Immune Modulation and Treatment of Solid Tumors with Antibodies that Specifically Bind CD38 |
| US10781261B2 (en) | 2015-11-03 | 2020-09-22 | Janssen Biotech, Inc. | Subcutaneous formulations of anti-CD38 antibodies and their uses |
| MA43187B1 (fr) | 2015-11-03 | 2021-02-26 | Janssen Biotech Inc | Formulations sous-cutanée d'anticorps anti-cd38 et leurs utilisations |
| CN112274649A (zh) * | 2015-12-10 | 2021-01-29 | 希望之城 | 细胞穿透花青偶联抗体 |
| WO2018002181A1 (en) | 2016-06-28 | 2018-01-04 | Umc Utrecht Holding B.V. | TREATMENT OF IgE-MEDIATED DISEASES WITH ANTIBODIES THAT SPECIFICALLY BIND CD38 |
| CN117866991A (zh) | 2016-10-07 | 2024-04-12 | 诺华股份有限公司 | 用于治疗癌症的嵌合抗原受体 |
| CA3046489A1 (en) | 2016-12-07 | 2018-06-14 | Progenity Inc. | Gastrointestinal tract detection methods, devices and systems |
| EP4108183A1 (en) | 2017-03-30 | 2022-12-28 | Biora Therapeutics, Inc. | Treatment of a disease of the gastrointestinal tract with an immune modulatory agent released using an ingestible device |
| WO2019089832A1 (en) | 2017-10-31 | 2019-05-09 | Janssen Biotech, Inc. | Methods of treating high risk multiple myeloma |
| US12227565B2 (en) | 2018-06-20 | 2025-02-18 | Biora Therapeutics, Inc. | Method of formulating a pharmaceutical composition comprising administering an immune modulator to the small intestine |
| WO2019246312A1 (en) | 2018-06-20 | 2019-12-26 | Progenity, Inc. | Treatment of a disease of the gastrointestinal tract with an immunomodulator |
| US20240252795A1 (en) | 2018-11-19 | 2024-08-01 | Biora Therapeutics, Inc. | Ingestible device for delivery of therapeutic agent to the gastrointestinal tract |
| KR20220079858A (ko) * | 2019-10-04 | 2022-06-14 | 추가이 세이야쿠 가부시키가이샤 | 오비누투주맙 내성 cd20 양성 암의 세포의 증식을 억제하는 제, 및 그에 관련된 의약 조성물, 의약, 제조, 세포의 증식을 억제하는 방법, 치료 방법, ii형 항cd20 항체, 화합물, 그들의 조합, 증강제 및 유도제 |
| CN121197633A (zh) | 2019-12-13 | 2025-12-26 | 比特比德科有限责任公司 | 用于将治疗剂递送至胃肠道的可摄取装置 |
| WO2023091887A1 (en) | 2021-11-16 | 2023-05-25 | Genentech, Inc. | Methods and compositions for treating systemic lupus erythematosus (sle) with mosunetuzumab |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3773919A (en) | 1969-10-23 | 1973-11-20 | Du Pont | Polylactide-drug mixtures |
| US5736137A (en) * | 1992-11-13 | 1998-04-07 | Idec Pharmaceuticals Corporation | Therapeutic application of chimeric and radiolabeled antibodies to human B lymphocyte restricted differentiation antigen for treatment of B cell lymphoma |
| EP1071700B1 (en) * | 1998-04-20 | 2010-02-17 | GlycArt Biotechnology AG | Glycosylation engineering of antibodies for improving antibody-dependent cellular cytotoxicity |
| RU2306952C2 (ru) * | 2001-01-31 | 2007-09-27 | Байоджен Айдек Инк. | Лечение в-клеточных злокачественных опухолей с использованием комбинации применений, связанных с антителами, уменьшающими количество b-клеток, и с иммуномодулирующими антителами |
| KR101348472B1 (ko) * | 2002-10-17 | 2014-01-07 | 젠맵 에이/에스 | Ｃｄ20에 대한 인간 모노클로날 항체 |
| CN103833854B (zh) * | 2002-12-16 | 2017-12-12 | 健泰科生物技术公司 | 免疫球蛋白变体及其用途 |
| LT2077282T (lt) * | 2003-11-05 | 2017-03-10 | Roche Glycart Ag | Antigeną surišančios molekulės su padidintu fc receptoriaus surišimo giminingumu ir efektoriaus funkcija |
| DOP2006000029A (es) * | 2005-02-07 | 2006-08-15 | Genentech Inc | Antibody variants and uses thereof. (variantes de un anticuerpo y usos de las mismas) |
| EP1891113A2 (en) * | 2005-06-02 | 2008-02-27 | AstraZeneca AB | Antibodies directed to cd20 and uses thereof |
| US20070071745A1 (en) * | 2005-08-26 | 2007-03-29 | Pablo Umana | Modified antigen binding molecules with altered cell signaling activity |
| MX2010002406A (es) * | 2007-09-05 | 2010-04-27 | Hoffmann La Roche | Terapia de combinacion con anticuerpos anti-cd20 de tipo i y de tipo ii. |
| DK2268310T3 (en) * | 2008-03-25 | 2016-08-15 | Roche Glycart Ag | APPLICATION OF A TYPE II ANTI-CD20 ANTIBODY WITH ENHANCED ANTIBODY-DEPENDENT CELLULAR CYTOTOXICITY (ADCC) IN COMBINATION WITH CYCLOPHOSPHAMIDE, VINCRISTIN AND DOXORUBICINE TO TREAT NON-HODGINE |
-
2009
- 2009-03-23 DK DK09723808.3T patent/DK2268310T3/en active
- 2009-03-23 LT LTEP09723808.3T patent/LT2268310T/lt unknown
- 2009-03-23 PT PT97238083T patent/PT2268310T/pt unknown
- 2009-03-23 MY MYPI2010004461A patent/MY163544A/en unknown
- 2009-03-23 HU HUE09723808A patent/HUE028828T2/en unknown
- 2009-03-23 AR ARP090101035A patent/AR072947A1/es unknown
- 2009-03-23 NZ NZ587284A patent/NZ587284A/en unknown
- 2009-03-23 WO PCT/EP2009/002111 patent/WO2009118142A1/en not_active Ceased
- 2009-03-23 KR KR1020107021332A patent/KR101280716B1/ko active Active
- 2009-03-23 MX MX2010009647A patent/MX2010009647A/es active IP Right Grant
- 2009-03-23 CL CL2009000713A patent/CL2009000713A1/es unknown
- 2009-03-23 RU RU2010143454/15A patent/RU2589704C2/ru active
- 2009-03-23 CN CN201611215290.7A patent/CN107198772A/zh active Pending
- 2009-03-23 EP EP09723808.3A patent/EP2268310B1/en active Active
- 2009-03-23 RS RS20160864A patent/RS55258B1/sr unknown
- 2009-03-23 US US12/408,746 patent/US20090246197A1/en not_active Abandoned
- 2009-03-23 JP JP2011501133A patent/JP5547709B2/ja active Active
- 2009-03-23 CN CN2009801101810A patent/CN101983071A/zh active Pending
- 2009-03-23 AU AU2009228616A patent/AU2009228616B2/en active Active
- 2009-03-23 HR HRP20161301TT patent/HRP20161301T1/hr unknown
- 2009-03-23 BR BRPI0909227A patent/BRPI0909227B8/pt active IP Right Grant
- 2009-03-23 SI SI200931530A patent/SI2268310T1/sl unknown
- 2009-03-23 ES ES09723808.3T patent/ES2592312T3/es active Active
- 2009-03-23 PL PL09723808T patent/PL2268310T3/pl unknown
- 2009-03-23 CA CA2716884A patent/CA2716884C/en active Active
- 2009-03-23 TW TW098109412A patent/TWI500624B/zh active
- 2009-03-24 PE PE2009000437A patent/PE20091821A1/es not_active Application Discontinuation
-
2010
- 2010-05-10 US US12/777,141 patent/US20100310581A1/en not_active Abandoned
- 2010-08-30 ZA ZA2010/06190A patent/ZA201006190B/en unknown
- 2010-09-03 MA MA33145A patent/MA32140B1/fr unknown
- 2010-09-06 IL IL208018A patent/IL208018A/en active IP Right Grant
- 2010-09-23 CR CR11687A patent/CR11687A/es unknown
-
2011
- 2011-03-07 US US13/042,305 patent/US20110177067A1/en not_active Abandoned
- 2011-10-28 US US13/284,415 patent/US20120301459A1/en not_active Abandoned
-
2013
- 2013-03-14 US US13/829,409 patent/US20140065134A1/en not_active Abandoned
-
2014
- 2014-01-24 JP JP2014011332A patent/JP5912142B2/ja active Active
- 2014-06-05 US US14/297,478 patent/US20160000911A1/en not_active Abandoned
-
2016
- 2016-03-18 JP JP2016055096A patent/JP6154039B2/ja active Active
- 2016-09-07 CY CY20161100889T patent/CY1117984T1/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL208018A0 (en) | Use of a type ii anti-cd20 antibody with increased antibody dependent cellular cytotoxicity (adcc) in combination with cyclophosphamide, vincristine and doxorubicine for treating non-hodgkin's lymphomas | |
| ZA201002773B (en) | Porcine dc-sign,icam-3 and lsectin and uses thereof | |
| IL254498B (en) | Peptidomimetic macrocyclic composition for use in the treatment of diseases | |
| EP1772126A4 (en) | DEVICE FOR PRODUCING ABSORBENT MATERIAL; ABSORBENT MATERIAL AND SUCTIONABLE ARTICLE | |
| EP1984175A4 (fr) | Materiau multi-couches, procede de fabrication et utilisation comme electrode | |
| IL200905A0 (en) | Compounds and compositions comprising the same for use in treating hepatitis c | |
| ZA200802274B (en) | Absorbent article with improved garment-like character | |
| EP2039817A4 (en) | ABSORBENT, MULTILAYER ABSORBENT AND ABSORBENT ARTICLE | |
| EP2367665A4 (en) | COMPOSITION AND PROCESS FOR TREATING WOOD-BASED MATERIAL AND WOOD-BASED MATERIAL PROCESSED WITH SAID COMPOSITION | |
| EP2246402A4 (en) | RESIN COMPOSITION, LAMINATE THEREFOR AND FORM BODY WITH LAMINATE | |
| EP2373274A4 (en) | VACUUM ARTICLE WITH ONE WAVE | |
| IL205939A (en) | Compounds for use in the treatment of lysosomal disorders | |
| EP1868435A4 (en) | COMBINATIONS, METHODS AND COMPOSITIONS FOR TREATING CANCER | |
| ZA200903771B (en) | Carbamate compounds for use in treating depression | |
| EP2213386A4 (en) | METHOD FOR WASHING A CYANO-CONTAINING FERTILIZER AND MICRO-ORGANISM FOR USE IN THE WASHING PROCESS | |
| EP2085061A4 (en) | METHOD OF MANUFACTURING ABSORBENT ARTICLE AND ABSORBENT ARTICLE | |
| PL2110241T3 (pl) | Materiał kompozytowy, zwłaszcza do elementów zapinających pieluchy, o wysokiej rozciągliwości i właściwościach półelastycznych | |
| GB2450812B (en) | Compound, ink, process and use | |
| EP2007838A4 (en) | MATERIAL ABSORBING INFRARED PROBES | |
| GB0708531D0 (en) | Process, compound, ink and use | |
| GB2435262B (en) | Method, composition and articles | |
| ZA200902612B (en) | Rubber composition for belt and rubber belt | |
| GB0612029D0 (en) | Compound, ink, process and use | |
| EP2150243A4 (en) | COMPOSITIONS AND METHODS FOR REINFORCED ACTIVE SUBSTANCE ABSORPTION | |
| GB0620089D0 (en) | Process, composition and ink |